News & Updates

Show Multimedia Only

Ongoing canagliflozin treatment beneficial to diabetic patients with CKD

11 Aug 2022

Treatment with the sodium‐glucose cotransporter 2 inhibitor canagliflozin protects against cardiovascular events in patients with comorbid type 2 diabetes (T2D) and chronic kidney disease (CKD), with a larger absolute benefit for total cardiovascular than first cardiovascular events, according to a post hoc analysis.

Ongoing canagliflozin treatment beneficial to diabetic patients with CKD

11 Aug 2022

Teclistamab demonstrates clinical activity for R/R MM

11 Aug 2022 by

The T-cell-redirecting bispecific antibody teclistamab induced deep and durable responses in patients with triple-class-exposed relapsed or refractory multiple myeloma (R/R MM), findings from the phase I/II MajesTEC-1 trial have shown.

Teclistamab demonstrates clinical activity for R/R MM

11 Aug 2022

1 week off methotrexate works okay for RA patients receiving flu shot

11 Aug 2022

Temporarily discontinuing methotrexate treatment for 1 week appears to induce satisfactory response to a seasonal influenza vaccine in patients with rheumatoid arthritis (RA), with a similar effect as a 2-week interruption schedule, according to a study.

1 week off methotrexate works okay for RA patients receiving flu shot

11 Aug 2022

Canagliflozin blunts end-stage renal disease risk in T2DM patients with CKD

11 Aug 2022

In patients with type 2 diabetes mellitus (T2DM) with chronic kidney disease (CKD), treatment with canagliflozin safely decreases the risk of developing end-stage renal disease, reports a new Japan study.

Canagliflozin blunts end-stage renal disease risk in T2DM patients with CKD

11 Aug 2022

Combination birth control pill effective across multiple subgroups

10 Aug 2022 by

Daily intake of the oral contraceptive pill that combines estetrol (E4) and drospirenone (DRSP) appears to be highly effective across subgroups defined by age, contraceptive history, and body mass index (BMI), according to pooled data from two pivotal phase III trials.

Combination birth control pill effective across multiple subgroups

10 Aug 2022

TNF-α antagonists superior to vedolizumab, ustekinumab for endoscopic healing in CD

10 Aug 2022 by

The tumour necrosis factor-alpha (TNF-α) antagonist therapies adalimumab and infliximab are more effective than vedolizumab and ustekinumab in achieving endoscopic healing (EH) at 1 year among patients with moderate-to-severe Crohn’s disease (CD), a recent study has shown.

TNF-α antagonists superior to vedolizumab, ustekinumab for endoscopic healing in CD

10 Aug 2022

Tools to predict adverse drug reactions in older adults lacking

10 Aug 2022

There is currently no standard and well-validated tool to predict adverse drug reactions (ADRs) in older adults, reports a recent meta-analysis.

Tools to predict adverse drug reactions in older adults lacking

10 Aug 2022

Ketamine holds up against fentanyl for procedural sedation in outpatient surgical abortion

10 Aug 2022

Intravenous treatment with ketamine is as good as that with fentanyl for procedural sedation in patients undergoing first-trimester outpatient surgical abortion, as reflected in patients’ satisfaction with their anaesthesia, according to a study.

Ketamine holds up against fentanyl for procedural sedation in outpatient surgical abortion

10 Aug 2022

Methenamine hippurate as good as antibiotic prophylaxis for recurrent UTI

10 Aug 2022 by

Daily antibiotics are the current guideline-recommended standard for urinary tract infection (UTI). Interestingly, in the randomized, open-label ALTAR trial presented at EAU 2022, the urinary antiseptic methenamine hippurate was noninferior to antibiotic prophylaxis in women with recurrent UTI.

Methenamine hippurate as good as antibiotic prophylaxis for recurrent UTI

10 Aug 2022

Dronedarone matches up to Asians with AF, atrial flutter

09 Aug 2022 by

Asians with atrial fibrillation (AF) or atrial flutter (AFL) do well with dronedarone, which lowers the risk of hospitalization for cardiovascular (CV) events or death from any cause to a similar extent as in non-Asian patients from the ATHENA trial, according to the results of a post hoc analysis.

Dronedarone matches up to Asians with AF, atrial flutter

09 Aug 2022

News & Updates

Filter by Specialty:

Specialty:

Ongoing canagliflozin treatment beneficial to diabetic patients with CKD

Ongoing canagliflozin treatment beneficial to diabetic patients with CKD

Teclistamab demonstrates clinical activity for R/R MM

Teclistamab demonstrates clinical activity for R/R MM

1 week off methotrexate works okay for RA patients receiving flu shot

1 week off methotrexate works okay for RA patients receiving flu shot

Canagliflozin blunts end-stage renal disease risk in T2DM patients with CKD

Canagliflozin blunts end-stage renal disease risk in T2DM patients with CKD

Combination birth control pill effective across multiple subgroups

Combination birth control pill effective across multiple subgroups

TNF-α antagonists superior to vedolizumab, ustekinumab for endoscopic healing in CD

TNF-α antagonists superior to vedolizumab, ustekinumab for endoscopic healing in CD

Tools to predict adverse drug reactions in older adults lacking

Tools to predict adverse drug reactions in older adults lacking

Ketamine holds up against fentanyl for procedural sedation in outpatient surgical abortion

Ketamine holds up against fentanyl for procedural sedation in outpatient surgical abortion

Methenamine hippurate as good as antibiotic prophylaxis for recurrent UTI

Methenamine hippurate as good as antibiotic prophylaxis for recurrent UTI

Dronedarone matches up to Asians with AF, atrial flutter

Dronedarone matches up to Asians with AF, atrial flutter